Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib

Published:2009-11-18 Issue:2 Volume:87 Page:197-203
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:
Short-container-title:Clin Pharmacol Ther

Author:

Tanaka C,Yin O Q P,Sethuraman V,Smith T,Wang X,Grouss K,Kantarjian H,Giles F,Ottmann O G,Galitz L,Schran H

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference22 articles.

1. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure

2. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)

3. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia

4. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

5. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy;Blood;2024-08-29

2. The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling;Molecular and Cellular Biochemistry;2024-07-15

3. Clinical pharmacokinetics and drug–drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective;Critical Reviews in Oncology/Hematology;2024-03

4. Pharmacology of Tyrosine Kinase Inhibitors;Clinical Journal of the American Society of Nephrology;2023-12-11

5. Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia;Pharmaceutics;2023-10-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3